Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]
News [7779]
Articles [63]
Editorials [9]
Conferences [208]
elearning [49]
The AZURE translational study
Prof Robert Coleman - Weston Park Hospital, University of Sheffield, UK
The AZURE translational study ( Prof Robert Coleman - Weston Park Hospital, University of Sheffield, UK )
14 Dec 2012
Diagnosis of blood cancer after a breast cancer diagnosis
Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA
Diagnosis of blood cancer after a breast cancer diagnosis ( Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA )
14 Dec 2012
Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic...
Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA
Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia ( Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA )
13 Dec 2012
HDAC inhibition sensitises triple-negative breast cancer cells to PARP...
Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA
HDAC inhibition sensitises triple-negative breast cancer cells to PARP inhibition ( Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA )
13 Dec 2012
Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell...
Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )
13 Dec 2012
A need for clarity in clinical trial end points
Dr Clifford Hudis – Memorial Sloan Kettering Cancer Center, New York, USA
A need for clarity in clinical trial end points ( Dr Clifford Hudis – Memorial Sloan Kettering Cancer Center, New York, USA )
13 Dec 2012
The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab
Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston...
The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab ( Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, USA )
13 Dec 2012
Uncovering new targets for treatment of chronic lymphocytic leukaemia
Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus...
Uncovering new targets for treatment of chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus, USA )
13 Dec 2012
Neratinib shows beneficial effects in the treatment of HER2 mutated breast...
Prof Ron Bose – Washington University School of Medicine, St. Louis, USA
Neratinib shows beneficial effects in the treatment of HER2 mutated breast cancer ( Prof Ron Bose – Washington University School of Medicine, St. Louis, USA )
12 Dec 2012
Breast cancer hypo-fractionated radiotherapy offers long-term tumour control
Prof John Yarnold – Institute of Cancer Research and Royal Marsden Hospital, UK
Breast cancer hypo-fractionated radiotherapy offers long-term tumour control ( Prof John Yarnold – Institute of Cancer Research and Royal Marsden Hospital, UK )
12 Dec 2012
Extending adjuvant trastuzumab treatment time provided no additional benefit
Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium
Extending adjuvant trastuzumab treatment time provided no additional benefit ( Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium )
12 Dec 2012
BEATRICE study, adjuvant bevacizumab did not improve invasive disease-free...
Prof David Cameron - Edinburgh University, UK
BEATRICE study, adjuvant bevacizumab did not improve invasive disease-free survival in triple-negative breast cancer ( Prof David Cameron - Edinburgh University, UK )
12 Dec 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation